Barriers to Tofersen Therapy for Variant SOD1-Mediated ALS

Stanley H Appel; Jason R Thonhoff

doi:10.1001/jamaneurol.2024.3331

Barriers to Tofersen Therapy for Variant SOD1-Mediated ALS

JAMA Neurol. 2024 Dec 1;81(12):1239-1240. doi: 10.1001/jamaneurol.2024.3331.

Authors

Stanley H Appel¹, Jason R Thonhoff¹

Affiliation

¹ Houston Methodist Neurological Institute, Houston Methodist Research Institute, Stanley H. Appel Department of Neurology, Houston Methodist Hospital, Houston, Texas.

PMID: 39373990
DOI: 10.1001/jamaneurol.2024.3331

No abstract available

Plain language summary

This Viewpoint advocates for the accelerated adoption of tofersen therapy to treat patients with variant SOD1-mediated amyotrophic lateral sclerosis (ALS) and describes the current barriers to treatment.